

MONKEY LRG1 SPARCL™ ASSAY

Life Diagnostics, Inc., Catalog Number: LRG-SP-3

BACKGROUND

Leucine-rich alpha-2-glycoprotein-1 (LRG1) is a 50 kDa protein that is primarily expressed in liver. In humans, it is a positive acute phase reactant; serum levels are elevated during chronic inflammatory diseases and infections (refs 1,2). It may also serve as a human biomarker for ovarian cancer (ref 4), B-cell acute lymphoblastic leukemia (ref 5) and Kawasaki disease (ref 6). In monkeys, LRG1 is a potential biomarker for rheumatoid arthritis (ref 7).

PRINCIPLE OF THE ASSAY

The monkey LRG1 SPARCL™¹ (Spatial Proximity Analyte Reagent Capture Luminescence, ref 3) assay uses two LRG1 antibody conjugates; one to horseradish peroxidase (HRP), the other to acridan, a chemiluminescent substrate. When HRP and acridan conjugated antibodies bind to LRG1 they are brought into proximity. With the addition of hydrogen peroxide, HRP catalyzes oxidation of proximal acridan molecules causing a flash of chemiluminescence. Acridan conjugated antibodies distant from HRP produce no signal. This principle allows the development of a homogeneous assay that allows rapid determination of LRG1 concentrations.

The HRP and acridan conjugated antibodies provided with the kit are mixed with standards and diluted samples in wells of the 96-well white SPARCL™ plate provided with the kit². After incubation for 30 minutes on a shaker at 25°C and 150 rpm, the plate is placed into a luminometer. Trigger solution containing hydrogen peroxide is injected into each well and luminescence is immediately measured. The concentration of LRG1 is proportional to luminescence and is derived from a standard curve.

MATERIALS AND COMPONENTS

Materials provided with the kit:

- Anti-LRG1 HRP conjugate **Store ≤ -70°C**
- Anti-LRG1 acridan conjugate **Store ≤ -70°C**
- LRG1 stock **Store ≤ -70°C**
- Diluent; CSD50-1, 2 x 50 ml
- Trigger solution; TS7-1, 7 ml
- White SPARCL™ plate (12 x 8-well)
- Clear untreated 96-well plate

Materials required but not provided:


- Precision pipettes and tips
- Polypropylene microcentrifuge tubes
- Vortex mixer
- Plate incubator/shaker
- Luminometer capable of simultaneous injection/measurement
- Curve fitting software

STORAGE

Store the HRP conjugate, acridan conjugate and LRG1 stock at or below -70°C. The remainder of the kit should be stored at 2-8°C. The SPARCL™ plate should be kept in a sealed bag with desiccant and antioxidant. The kit will remain stable for at least six months from the date of purchase, provided that the components are stored as described.

GENERAL INSTRUCTIONS

1. Please take the time to completely read all instructions before starting your assay. Contact us if you need clarification.
2. All reagents used in the assay should be allowed to reach room temperature (25°C) before use.
3. It is important that standards and samples be added to the SPARCL™ plate quickly. If testing large numbers of samples, rather than pipetting standards and samples directly into the white SPARCL™ plate using a single channel pipettor, we recommend the following. First, pipette an excess volume of standards and samples into appropriate wells of the clear 96-well plate. Then use an 8- or 12-channel multipipettor to quickly and efficiently transfer 50 µl aliquots to the appropriate wells of the white SPARCL™ plate. The wells of the clear plate have a maximum volume of 300 µl.
4. Follow the sequence of events below when running the assay.



STANDARD PREPARATION

The LRG1 stock is comprised of pure monkey LRG1 diluted in a stabilizing carrier protein matrix.

1. Thaw the LRG1 stock shortly before use.
2. Label 8 polypropylene tubes as 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78 ng/ml.
3. Into the tube labeled 100 ng/ml, pipette the volume of diluent detailed on the stock vial label. Then add the indicated volume of stock and mix gently. This provides the 100 ng/ml standard.
4. Dispense 150 µl of diluent into the tubes labeled 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78 ng/ml.
5. Pipette 150 µl of the 100 ng/ml LRG1 standard into the tube labeled 50 ng/ml and mix. This provides the 50 ng/ml LRG1 standard.
6. Similarly prepare the remaining standards by two-fold serial dilution.

If future use of the LRG1 stock is intended, it should be stored frozen at or below -70°C.

¹ The SPARCL™ technology was developed by Lumigen Corp.

² The white SPARCL™ plate provided with the kit has been treated with a reagent that reduces background chemiluminescence. Untreated plates cannot be used.

SAMPLE PREPARATION

In studies at Life Diagnostics we found that LRG1 is a positive acute phase reactant in rhesus monkeys. Baseline levels were 8.8 ± 1.8 $\mu\text{g/ml}$ (mean \pm SD, n=6). During the acute phase response, levels increased to 49.2 ± 21.1 $\mu\text{g/ml}$ (mean \pm SD, n=5)³.

To obtain RLU values within range of the standard curve we recommend that serum and plasma be diluted 1000-fold prior to assay. Only use the diluent provided with the kit. Do not test samples at dilutions lower than 100-fold.

CONJUGATE MIX PREPARATION

Instructions for preparation of the conjugate mix are detailed on the box that contains the HRP and acridan conjugates. Prepare the mix shortly before use using the diluent provided with the kit.

LUMINOMETER SETUP

1. The luminometer must be capable of injection and simultaneous measurement of luminescence without any delay.
2. Prime the luminometer injection port with at least 1 ml of trigger solution.
3. Place the injection needle into the injection port, (necessary for BMG luminometers).
4. Program the luminometer to inject 37.5 μl of trigger solution per well and to measure from time zero for 1 second (50 x 0.02 second intervals).
5. Define the format of the assay using the luminometer software.
6. Because the white SPARCL™ plate is provided as a 12 x 8-well strips, allowing use of fewer than 96-wells, make sure that the luminometer is programmed to inject trigger solution only into the wells being used.
7. We use a BMG LUMIstar Omega set at a gain of 3600. Optimal gain should be determined by the end user.
8. There are a number of manufacturers of luminometers that are equipped to run a SPARCL™ assay. Please contact Life Diagnostics or Lumigen (www.lumigen.com) to discuss your luminometer.

PROCEDURE

1. Before starting the assay ensure that the luminometer is primed with trigger solution and that the injection needle is positioned in the injection port.
2. Secure the desired number of SPARCL™ 8-well strips in the holder. Immediately seal unused strips in the resealable bag with desiccant and antioxidant. Store unused strips at 2-8°C.
3. Aliquot 25.0 μl of conjugate mix into each well.
4. Dispense 50.0 μl of standards and diluted samples into the wells (we recommend that standards and samples be tested in duplicate).
5. Incubate on an orbital micro-plate shaker at 150 rpm 25°C for 30 minutes.
6. After the 30-minute incubation, place the plate in the luminometer and measure luminescence after injection of trigger solution (37.5 μl).
7. Remove the plate from the luminometer and discard the used strips. Keep the plate frame if future use is intended.

CALCULATION OF RESULTS

1. Before calculating results, review the raw data. If artefacts (RLU spikes) are apparent immediately after injection of trigger solution, eliminate that portion of the luminescence profile from


analysis for all wells. We routinely use the sum of RLU values from a 100-980 ms data collection window.

2. Determine the sum of RLU values within the data collection window for the standards and samples.
3. Using graphing software, construct a standard curve by plotting the sum of the RLU values for the standards versus the \log_{10} of LRG1 concentration and fit to a sigmoidal, 4PL model.
4. Derive the corresponding concentration of LRG1 in the samples from the standard curve (remember to derive the concentration from the antilog).
5. Multiply the derived concentration by the dilution factor to determine the concentration of LRG1 in the original sample.
6. If the sum of the RLU values of diluted samples fall outside the standard curve, samples should be appropriately diluted and re-tested.

TYPICAL STANDARD CURVE

A typical standard curve is shown below. This curve is for illustration only and should not be used to calculate unknowns. A standard curve should be run with each experiment.

LRG1 (ng/ml)	RLU
100	17709
50	10700
25	7861
12.5	3967
6.25	2461
3.13	1163
1.56	759
0.78	597



REFERENCES

1. Ha YJ. et. al. Usefulness of serum leucine-rich alpha-2-glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis. *J Korean Med Sci.* 29:1199-1204 (2014)
2. Weivoda S. et. al. ELISA for human leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. *J Immunol Methods.* 336:22-29 (2008)
3. Akhavan-Tafti H. et al. A homogeneous chemiluminescent immunoassay method. *J Am Chem Soc.* 20;135(11):4191-4 (2013)
4. Andersen JD. et. al. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. *Journal of Ovarian Research* 2010, 3:21. <https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-3-21>

³ Plasma samples were kindly provided by Dr. Natalia Ossetrova, AFRR1.

5. de Souza Cavalcante M. et. al. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment of B-cell acute lymphoblastic leukemia. *Biomarker Research* (2016) 4:1. <https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-016-0055-6>
6. Kimura, Y. et. al. Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis. (2017) <https://www.nature.com/articles/srep43732>
7. Fujimoto M. et al. Leucine-rich α 2-glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. *Arthritis & Rheumatology* 67(8):2056-2060 (2015).

Rev 022018

For technical assistance please email us at
techsupport@lifediagnosics.com